• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发现硫菁染料作为一类新型强效冠状病毒抑制剂,可抑制病毒RNA合成。

Discovery of thiacyanine dyes as a new class of potent coronavirus inhibitors that suppress viral RNA synthesis.

作者信息

Zhang Tianyi, Altouma Valerie, Sommers Joshua A, Dumm Adaira J, Kennedy Debbie, Xia Hongjie, Yang Mo, Fullenkamp Christopher R, Huang Shar-Yin N, Xue Yutong, Su Shuaikun, Shen Weiping, Haren Caitlin E, Kulikowicz Tomasz, Pommier Yves, Schneekloth John S, Garcia-Blanco Mariano A, Brosh Robert M, Wang Weidong

机构信息

Lab of Genetics and Genomics, National Institute on Aging, NIH, Baltimore, Maryland, USA.

Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, Maryland, USA.

出版信息

J Biol Chem. 2025 Aug 5;301(9):110547. doi: 10.1016/j.jbc.2025.110547.

DOI:10.1016/j.jbc.2025.110547
PMID:40752578
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12423399/
Abstract

Topoisomerase poisons are clinically used anticancer drugs that can induce DNA cleavage complexes to block replication. TOP3B is the only topoisomerase that can catalyze topological changes on either DNA or RNA and induce cleavage complexes on both nucleic acids. We proposed that TOP3B poisons may inhibit coronavirus RNA genome replication and tested this hypothesis by using mouse hepatitis coronavirus (MHV). We found that one of the two types of reported TOP3B poisons, thiacyanine dyes, possess potent inhibitory activities for MHV. Interestingly, the antiviral activity of the thiacyanine dyes is unaltered in Top3b-KO cells, suggesting that these dyes inhibit viral replication independent of TOP3B. Subsequent screening revealed that multiple members of the thiacyanine dye family have antiviral activity comparable to or stronger than remdesivir, the U.S. Food and Drug Administration (FDA)-approved drug for coronavirus, in an MHV-infected cell line model. One thiacyanine dye (NSC93472) significantly inhibits MHV replication in mouse lungs, showing its potential as an anticoronavirus drug. Mechanistic studies showed that NSC93472 preferentially binds two RNA fragments derived from SARS-CoV-2 genome over random ssRNA, interferes with assembly of an elongation-competent complex between the viral RNA-dependent RNA polymerase and the RNA template, and inhibits the RNA synthesis mediated by the RNA-dependent RNA polymerase. Moreover, NSC93472 can inhibit RNA synthesis by the reverse transcriptase of Moloney murine leukemia virus. Our studies demonstrate that thiacyanine dyes represent a new family of coronavirus inhibitors and suggest that TOP3B poisons and anti-RNA virus drugs share common characteristics in RNA binding and inhibition of enzymatic reactions on RNA.

摘要

拓扑异构酶毒物是临床上使用的抗癌药物,可诱导DNA裂解复合物来阻断复制。TOP3B是唯一一种能够催化DNA或RNA拓扑变化并在两种核酸上诱导裂解复合物的拓扑异构酶。我们提出TOP3B毒物可能抑制冠状病毒RNA基因组复制,并通过使用小鼠肝炎冠状病毒(MHV)来验证这一假设。我们发现,已报道的两种TOP3B毒物之一,硫代花青染料,对MHV具有强大的抑制活性。有趣的是,硫代花青染料的抗病毒活性在Top3b基因敲除细胞中未改变,这表明这些染料抑制病毒复制不依赖于TOP3B。随后的筛选显示,在MHV感染的细胞系模型中,硫代花青染料家族的多个成员具有与美国食品药品监督管理局(FDA)批准的抗冠状病毒药物瑞德西韦相当或更强的抗病毒活性。一种硫代花青染料(NSC93472)显著抑制小鼠肺部的MHV复制,显示出其作为抗冠状病毒药物的潜力。机制研究表明,NSC93472优先结合源自严重急性呼吸综合征冠状病毒2(SARS-CoV-2)基因组的两个RNA片段而非随机单链RNA,干扰病毒RNA依赖性RNA聚合酶与RNA模板之间延伸能力复合物的组装,并抑制由RNA依赖性RNA聚合酶介导的RNA合成。此外,NSC93472可抑制莫洛尼鼠白血病病毒逆转录酶的RNA合成。我们的研究表明,硫代花青染料代表了一类新的冠状病毒抑制剂,并表明TOP3B毒物和抗RNA病毒药物在RNA结合和抑制RNA酶促反应方面具有共同特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307d/12423399/548890009d11/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307d/12423399/bd481f03259c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307d/12423399/1166c0cd58b1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307d/12423399/90ec5244dea5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307d/12423399/627a4b2ff9d6/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307d/12423399/548890009d11/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307d/12423399/bd481f03259c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307d/12423399/1166c0cd58b1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307d/12423399/90ec5244dea5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307d/12423399/627a4b2ff9d6/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307d/12423399/548890009d11/gr5.jpg

相似文献

1
Discovery of thiacyanine dyes as a new class of potent coronavirus inhibitors that suppress viral RNA synthesis.发现硫菁染料作为一类新型强效冠状病毒抑制剂,可抑制病毒RNA合成。
J Biol Chem. 2025 Aug 5;301(9):110547. doi: 10.1016/j.jbc.2025.110547.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
4
2-Bromopalmitate depletes lipid droplets to inhibit viral replication.2-溴十六烷酸酯通过消耗脂滴来抑制病毒复制。
J Virol. 2024 Apr 16;98(4):e0017124. doi: 10.1128/jvi.00171-24. Epub 2024 Mar 15.
5
Aspects of Genetic Diversity, Host Specificity and Public Health Significance of Single-Celled Intestinal Parasites Commonly Observed in Humans and Mostly Referred to as 'Non-Pathogenic'.人类常见且大多被称为“非致病性”的单细胞肠道寄生虫的遗传多样性、宿主特异性及公共卫生意义
APMIS. 2025 Sep;133(9):e70036. doi: 10.1111/apm.70036.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
7
A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance.冠状病毒 nsp13-解旋酶的突变会损害其酶活性,并赋予瑞德西韦部分耐药性。
mBio. 2023 Aug 31;14(4):e0106023. doi: 10.1128/mbio.01060-23. Epub 2023 Jun 20.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
9
Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.免疫蛋白酶体抑制对小鼠肝炎病毒1型急性呼吸道感染的影响。
J Virol. 2024 Dec 17;98(12):e0123824. doi: 10.1128/jvi.01238-24. Epub 2024 Nov 7.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.

本文引用的文献

1
SARS-CoV-2 point mutations are over-represented in terminal loops of RNA stem-loop structures that can be resolved by Nsp13 helicase in a unique manner with respect to nucleotide dependence.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的点突变在RNA茎环结构的末端环中过度呈现,这些末端环可被Nsp13解旋酶以一种独特的、依赖核苷酸的方式解开。
Nucleic Acids Res. 2025 May 22;53(10). doi: 10.1093/nar/gkaf447.
2
Identification and characterization of topoisomerase III beta poisons.拓扑异构酶 IIIβ 抑制剂的鉴定与特性研究。
Proc Natl Acad Sci U S A. 2023 Aug 22;120(34):e2218483120. doi: 10.1073/pnas.2218483120. Epub 2023 Aug 14.
3
RNA binding protein PRRC2B mediates translation of specific mRNAs and regulates cell cycle progression.
RNA 结合蛋白 PRRC2B 介导特定 mRNA 的翻译,并调节细胞周期进程。
Nucleic Acids Res. 2023 Jun 23;51(11):5831-5846. doi: 10.1093/nar/gkad322.
4
Biochemical analysis of SARS-CoV-2 Nsp13 helicase implicated in COVID-19 and factors that regulate its catalytic functions.SARS-CoV-2 Nsp13 解旋酶在 COVID-19 中的生化分析及其催化功能调节因子。
J Biol Chem. 2023 Mar;299(3):102980. doi: 10.1016/j.jbc.2023.102980. Epub 2023 Feb 4.
5
Topoisomerase 3b is dispensable for replication of a positive-sense RNA virus--murine coronavirus.拓扑异构酶 3b 对于正链 RNA 病毒——鼠冠状病毒的复制是可有可无的。
Antiviral Res. 2022 Dec;208:105451. doi: 10.1016/j.antiviral.2022.105451. Epub 2022 Oct 31.
6
RNA Viruses, Pandemics and Anticipatory Preparedness.RNA 病毒、大流行和预期准备。
Viruses. 2022 Sep 30;14(10):2176. doi: 10.3390/v14102176.
7
Photonics of Trimethine Cyanine Dyes as Probes for Biomolecules.三嗪花青染料的光子学作为生物分子的探针。
Molecules. 2022 Sep 27;27(19):6367. doi: 10.3390/molecules27196367.
8
A dual-activity topoisomerase complex regulates mRNA translation and turnover.一种双活性拓扑异构酶复合物调节 mRNA 翻译和周转。
Nucleic Acids Res. 2022 Jul 8;50(12):7013-7033. doi: 10.1093/nar/gkac538.
9
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.索磷布韦/维帕他韦联合治疗早期轻度至中度 COVID-19 患者的疗效和安全性。
Sci Rep. 2022 Apr 6;12(1):5771. doi: 10.1038/s41598-022-09741-5.
10
Effect of sofosbuvir-based treatment on clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials.基于索磷布韦的治疗对 COVID-19 患者临床结局的影响:随机对照试验的系统评价和荟萃分析。
Int J Antimicrob Agents. 2022 Mar;59(3):106545. doi: 10.1016/j.ijantimicag.2022.106545. Epub 2022 Feb 6.